Respiratory nurse lead Carol Stonham outlines what nurses in primary care need to know about changes in the diagnosis and ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

another LABA/LAMA/ICS combination – is approved for chronic obstructive pulmonary disease (COPD) but was only filed for approval as an asthma therapy in Europe in February, so looks set to be ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

Tibet, Potala Palace, Lhasa – the traditional home of the Dalai Lama – had a hold on her since poring over ... She recalls ...

Also in November 2024, the Company completed enrollment in a Phase 2 dose-ranging trial with glycopyrrolate, a LAMA, supporting ... cystic fibrosis, asthma and other respiratory diseases.

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

At the moment, the recommended treatment for COPD in Europe is an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA), or LABA/LAMA dual ...

Part two of this series sees Ravijyot Saggu explore pharmacological management recommendations from the new joint chronic ...